BCAX Stock Price | Bicara Therapeutics Inc. Common Stock P/E, Revenue, EPS, & Forecasts

Bicara Therapeutics Inc. Common Stock • BCAX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Bicara Therapeutics Inc. Common Stock

Ticker

BCAX

Trading on

NASDAQ

ISIN

US0554771032

Industry

Biotechnology

Sector

Healthcare

CEO

Claire Mazumdar Clemon M.B.A., Ph.D.

Headquarters

116 Huntington Avenue, Boston, MA, United States, 02116

Employees

Website

bicara.com

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Metrics

BasicAdvanced

Market cap

$901M

P/E ratio

EPS

-$3.75

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-58.3M

Ex dividend date

Price & volume

Market cap

$901M

Average daily volume

0.6M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

1.77

Earnings

EPS

-$3.75

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-58.3M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

52-week High

$28.09

52-week Low

$11.10

50-day moving average

$25.24

200-day moving average

$25.24

Short ratio

Short %

0.00%

Management effectiveness

ROE (TTM)

0.00%

ROA (TTM)

0.00%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

54.4M

Float

29.6M

Insiders %

0.42%

Institutions %

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$-14.8M

0.00%

Q2 • 24

$0M

$-17.5M

∞%

Q3 • 24

NaN%

18.29%

0.00%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$209M

$384M

183.71%

Q2 • 24

$524M

$14.6M

2.79%

Q3 • 24

151.06%

96.19%

98.48%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-13.7M

$0.4M

$-13.8M

Q2 • 24

$-17.2M

$-0M

$334M

$-17.2M

Q3 • 24

25.29%

76,624.45%

25.24%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Bicara Therapeutics Inc. Common Stock share?

Bicara Therapeutics Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Bicara Therapeutics Inc. Common Stock have?

Bicara Therapeutics Inc. Common Stock currently has 54.4M shares.

Does Bicara Therapeutics Inc. Common Stock pay dividends?

No, Bicara Therapeutics Inc. Common Stock doesn't pay dividends.

What is Bicara Therapeutics Inc. Common Stock 52 week high?

Bicara Therapeutics Inc. Common Stock 52 week high is $28.09.

What is Bicara Therapeutics Inc. Common Stock 52 week low?

Bicara Therapeutics Inc. Common Stock 52 week low is $11.10.

What is the 200-day moving average of Bicara Therapeutics Inc. Common Stock?

Bicara Therapeutics Inc. Common Stock 200-day moving average is $25.24.

Who is Bicara Therapeutics Inc. Common Stock CEO?

The CEO of Bicara Therapeutics Inc. Common Stock is Claire Mazumdar Clemon M.B.A., Ph.D..

How many employees Bicara Therapeutics Inc. Common Stock has?

Bicara Therapeutics Inc. Common Stock has 0 employees.

What is the market cap of Bicara Therapeutics Inc. Common Stock?

The market cap of Bicara Therapeutics Inc. Common Stock is $901M.

What is the P/E of Bicara Therapeutics Inc. Common Stock?

The current P/E of Bicara Therapeutics Inc. Common Stock is null.

What is the EPS of Bicara Therapeutics Inc. Common Stock?

The EPS of Bicara Therapeutics Inc. Common Stock is -$3.75.

What is the PEG Ratio of Bicara Therapeutics Inc. Common Stock?

The PEG Ratio of Bicara Therapeutics Inc. Common Stock is null.